期刊
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS
卷 45, 期 4, 页码 380-384出版社
WILEY
DOI: 10.1111/jvp.13065
关键词
Apoquel; chewable; dog; film-coated tablet; IL-31; JAK; oclacitinib maleate; onset of action; pruritus
资金
- Zoetis
This study aimed to determine if a flavored chewable formulation of oclacitinib provides a similar onset of anti-pruritic activity as the original film-coated tablets. The results showed that the new chewable formulation effectively reduced IL-31-induced pruritus in dogs within 1-3 hours, comparable to the film-coated tablets.
Oclacitinib maleate (Apoquel (R), Zoetis Inc.) is commonly used around the world for the control/treatment of pruritus associated with allergic dermatitis and the control/treatment of atopic dermatitis in dogs at least 12 months of age. A new flavored chewable formulation of oclacitinib has been developed where more than 90% of doses offered to dogs were freely accepted when tested in clinical trials. The objective of this study was to determine whether the new chewable formulation of oclacitinib has a similar onset of anti-pruritic activity as the original oclacitinib film-coated tablets (FCT). Twenty-one laboratory beagle dogs were randomized to treatment and received placebo, 0.4-0.6 mg/kg oclacitinib FCT or 0.4-0.6 mg/kg flavored chewable oclacitinib tablet (n = 7/group). Efficacy was measured by assessing reduction in pruritus 1-3 h post-administration of treatments. Pruritus was induced by injecting canine IL-31, intravenously (2.5 mu g/kg), approximately 15 min prior to the pruritus observation window. Results from this study demonstrated both oclacitinib FCT and the flavored chewable oclacitinib tablet significantly reduced IL-31-induced pruritus within 1-3 h post-dosing compared to placebo (p = .0069 and .0113, respectively), suggesting the new formulation of oclacitinib chewable tablets works as quickly to reduce pruritus in dogs as the oclacitinib FCT.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据